Summary

Market Summary:
As per Market Research Future analysis, the Japan neuropsychiatric disorders-treatment market size was estimated at 7.5 USD Billion in 2024. The Japan neuropsychiatric disorders-treatment market is projected to grow from 8.37 USD Billion in 2025 to 25.0 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 11.5% during the forecast period 2025 - 2035

Market Drivers:
The increasing awareness and education surrounding mental health issues in Japan are crucial drivers for the neuropsychiatric disorders-treatment market. Educational programs aimed at both healthcare professionals and the general public are fostering a better understanding of neuropsychiatric disorders. This heightened awareness is likely to lead to earlier diagnosis and treatment, which can significantly improve patient outcomes. Surveys indicate that over 60% of Japanese citizens now recognize the importance of mental health, compared to just 30% a decade ago. As stigma diminishes and knowledge expands, more individuals are expected to seek treatment, thereby propelling the growth of the neuropsychiatric disorders-treatment market. Government initiatives aimed at improving mental health care in Japan significantly influence the neuropsychiatric disorders-treatment market. The Japanese government has implemented various policies to enhance mental health services, including increased funding for research and treatment programs. In 2023, the government allocated approximately ¥200 billion to mental health initiatives, reflecting a commitment to addressing the growing mental health crisis.

Market Segment Analysis:
Japan Neuropsychiatric Disorders Treatment Market Segment Insights Neuropsychiatric Disorders Treatment Market Type Insights The Japan Neuropsychiatric Disorders Treatment Market is increasingly structured around various types of disorders, leading to significant advancements in treatment and care. The classification includes degenerative diseases, neurotic disorders, psychosis, and others, each presenting unique characteristics and treatment approaches. Degenerative diseases, such as Alzheimer's and Parkinson's, are particularly crucial due to the aging population in Japan, which faces a growing prevalence of cognitive impairments and neurological decline. Neurotic disorders encompass a range of anxiety and mood disorders that significantly impact daily functioning and quality of life.Treatments in this area continue to evolve, reflecting societal changes and increased awareness of mental health issues. Psychosis, which includes conditions like schizophrenia, calls for an urgent need for effective therapeutic options as societal stigma often hinders diagnosis and access to care, making education and innovation key priorities.

Regional Analysis:
The neuropsychiatric disorders-treatment market is currently experiencing notable developments. This growth is driven by a combination of increasing awareness and advancements in therapeutic options.. In Japan, the prevalence of neuropsychiatric disorders has prompted a growing demand for effective treatment solutions. This trend is further supported by government initiatives aimed at improving mental health services and reducing the stigma associated with these conditions. As a result, healthcare providers are increasingly focusing on integrating innovative therapies, including pharmacological and non-pharmacological approaches, to enhance patient outcomes. Moreover, the landscape of the neuropsychiatric disorders-treatment market is evolving with the introduction of digital health technologies.

Major Players:
The following companies are key participants in the Japan Neuropsychiatric Disorders Treatment Market, playing a crucial role in market development through technological innovation, strategic partnerships, and competitive product offerings.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
EXECUTIVE SUMMARY
Market Overview
Key Findings
Market Segmentation
Competitive Landscape
Challenges and Opportunities
Future Outlook

2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
MARKET INTRODUCTION
Definition
Scope of the study
Research Objective
Assumption
Limitations
RESEARCH METHODOLOGY
Overview
Data Mining
Secondary Research
Primary Research
Primary Interviews and Information Gathering Process
Breakdown of Primary Respondents
Forecasting Model
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Data Triangulation
Validation

3 SECTION III: QUALITATIVE ANALYSIS
MARKET DYNAMICS
Overview
Drivers
Restraints
Opportunities
MARKET FACTOR ANALYSIS
Value chain Analysis
Porter's Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Intensity of Rivalry
COVID-19 Impact Analysis
Market Impact Analysis
Regional Impact
Opportunity and Threat Analysis

4 SECTION IV: QUANTITATIVE ANALYSIS
Japan Healthcare Market Segmentation
Japan Healthcare By Application (USD Billion, 2025-2035)
Depression
Anxiety Disorders
Bipolar Disorder
Schizophrenia
Obsessive-Compulsive Disorder
Healthcare By Treatment Type (USD Billion, 2025-2035)
Pharmacological Treatment
Psychotherapy
Electroconvulsive Therapy
Transcranial Magnetic Stimulation
Cognitive Behavioral Therapy
Healthcare By Patient Type (USD Billion, 2025-2035)
Adults
Children
Adolescents
Geriatric Population
Pregnant Women
Healthcare By Route of Administration (USD Billion, 2025-2035)
Oral
Intravenous
Intramuscular
Transdermal
Inhalation SECTION V: COMPETITIVE ANALYSIS
Competitive Landscape
Overview
Competitive Analysis
Market share Analysis
Major Growth Strategy in the neuropsychiatric disorders treatment market
Competitive Benchmarking
Leading Players in Terms of Number of Developments in the neuropsychiatric disorders treatment market
Key developments and growth strategies
New Product Launch/Service Deployment
Merger & Acquisitions
Joint Ventures
Major Players Financial Matrix
Sales and Operating Income
Major Players R&D Expenditure. 2023
Company Profiles
Takeda Pharmaceutical Company Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Otsuka Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Astellas Pharma Inc.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Eisai Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Daiichi Sanky
Company, Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Mitsubishi Tanabe Pharma Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Shionogi & Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Kyowa Kirin Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Appendix
References
Related Reports

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
LIST OF ASSUMPTIONS
Japan NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET SIZE ESTIMATES; FORECAST
TABLE 1 BY DISORDERS, 2026-2035 (USD Billion)
TABLE 2 BY DISORDERS, 2026-2035 (USD Billion)
TABLE 3 BY TREATMENT, 2026-2035 (USD Billion)
TABLE 4 BY TREATMENT, 2026-2035 (USD Billion)
TABLE 5 BY END USER, 2026-2035 (USD Billion)
TABLE 6 BY END USER, 2026-2035 (USD Billion)
PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
ACQUISITION/PARTNERSHIP

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET ANALYSIS BY DISORDERS
FIGURE 3 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET ANALYSIS BY TREATMENT
FIGURE 4 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET ANALYSIS BY END USER
FIGURE 5 KEY BUYING CRITERIA OF NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET
FIGURE 6 RESEARCH PROCESS OF MRFR
FIGURE 7 DRO ANALYSIS OF JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET
FIGURE 8 DRIVERS IMPACT ANALYSIS: JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET
FIGURE 9 RESTRAINTS IMPACT ANALYSIS: JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET
FIGURE 10 SUPPLY / VALUE CHAIN: JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET
FIGURE 11 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET, BY DISORDERS, 2024 (% SHARE)
FIGURE 12 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET, BY DISORDERS, 2024 TO 2035 (USD Billion)
FIGURE 13 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET, BY TREATMENT, 2024 (% SHARE)
FIGURE 14 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET, BY TREATMENT, 2024 TO 2035 (USD Billion)
FIGURE 15 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET, BY END USER, 2024 (% SHARE)
FIGURE 16 JAPAN NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET, BY END USER, 2024 TO 2035 (USD Billion)
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS